Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV16 E6 siRNA is a small interfering RNA designed to silence the expression of the HPV16 E6 oncoprotein. In high-risk human papillomavirus (HPV) infections, particularly HPV16, the E6 protein promotes oncogenesis by inducing the degradation of the tumor suppressor p53 and by activating the pluripotency factor OCT4. By targeting the E6 mRNA for degradation via the RNA-induced silencing complex (RISC), this siRNA restores p53 levels and reduces OCT4 expression, thereby inhibiting cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in cervical cancer cells. It is primarily used as a research tool to investigate the molecular mechanisms of HPV-driven carcinogenesis and as a potential therapeutic candidate for HPV-associated malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HPV16 E6 siRNA.